Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INaMICRON
NCT07380919Phase 3Recruiting
- Sponsor
- University of Naples Federico II
- Start
- Feb 2026
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ranolazine in ST elevation myocardial infarction (STEMI) and Coronary Microvascular Dysfunction (CMD) (2 arms), sponsored by University of Naples Federico II. Primary endpoint: Preservation of the coronary microcirculation at 8 weeks. Started Feb 2026; status: recruiting.
02
Drugs
ranolazine
03
Conditions
ST elevation myocardial infarction (STEMI)Coronary Microvascular Dysfunction (CMD)
Beyond the preview
Go deeper on NCT07380919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07380919.